PMID- 31307548
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20200526
IS  - 2523-3548 (Electronic)
IS  - 2523-3548 (Linking)
VI  - 39
IP  - 1
DP  - 2019 Jul 15
TI  - Impaired dendritic cell functions in lung cancer: a review of recent advances and 
      future perspectives.
PG  - 43
LID - 10.1186/s40880-019-0387-3 [doi]
LID - 43
AB  - Lung cancer is the leading cause of cancer mortality worldwide. Dendritic cells 
      (DCs) are the key factors providing protective immunity against lung tumors and 
      clinical trials have proven that DC function is reduced in lung cancer patients. 
      It is evident that the immunoregulatory network may play a key role in the 
      failure of the immune response to terminate tumors. Lung tumors likely employ 
      numerous strategies to suppress DC-based anti-tumor immunity. Here, we summarize 
      the recent advances in our understanding on lung tumor-induced immunosuppression 
      in DCs, which affects the initiation and development of T-cell responses. We also 
      describe which existing measures to restore DC function may be useful for 
      clinical treatment of lung tumors. Furthering our knowledge of how lung cancer 
      cells alter DC function to generate a tumor-supportive environment will be 
      essential in order to guide the design of new immunotherapy strategies for 
      clinical use.
FAU - Wang, Jing-Bo
AU  - Wang JB
AD  - Translational Medicine Collaborative Innovation Center, The Second Clinical 
      Medical College, Shenzhen People's Hospital, Jinan University, 1017 Dongmen Road 
      North, Shenzhen, 518020, Guangdong, P. R. China.
AD  - Shenzhen Cell Therapy Public Service Platform, Shenzhen, 218020, Guangdong, P. R. 
      China.
FAU - Huang, Xue
AU  - Huang X
AD  - Translational Medicine Collaborative Innovation Center, The Second Clinical 
      Medical College, Shenzhen People's Hospital, Jinan University, 1017 Dongmen Road 
      North, Shenzhen, 518020, Guangdong, P. R. China.
AD  - Shenzhen Cell Therapy Public Service Platform, Shenzhen, 218020, Guangdong, P. R. 
      China.
FAU - Li, Fu-Rong
AU  - Li FR
AUID- ORCID: 0000-0002-0606-8861
AD  - Translational Medicine Collaborative Innovation Center, The Second Clinical 
      Medical College, Shenzhen People's Hospital, Jinan University, 1017 Dongmen Road 
      North, Shenzhen, 518020, Guangdong, P. R. China. frli62@163.com.
AD  - Shenzhen Cell Therapy Public Service Platform, Shenzhen, 218020, Guangdong, P. R. 
      China. frli62@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190715
PL  - United States
TA  - Cancer Commun (Lond)
JT  - Cancer communications (London, England)
JID - 101723675
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Lung Neoplasms/*immunology
PMC - PMC6631514
OTO - NOTNLM
OT  - Dendritic cell
OT  - Immune regulation
OT  - Immunotherapy
OT  - Lung cancer
COIS- The authors declare that they have no competing interests.
EDAT- 2019/07/17 06:00
MHDA- 2020/05/27 06:00
PMCR- 2019/07/15
CRDT- 2019/07/17 06:00
PHST- 2018/12/03 00:00 [received]
PHST- 2019/07/03 00:00 [accepted]
PHST- 2019/07/17 06:00 [entrez]
PHST- 2019/07/17 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
PHST- 2019/07/15 00:00 [pmc-release]
AID - 10.1186/s40880-019-0387-3 [pii]
AID - 387 [pii]
AID - 10.1186/s40880-019-0387-3 [doi]
PST - epublish
SO  - Cancer Commun (Lond). 2019 Jul 15;39(1):43. doi: 10.1186/s40880-019-0387-3.